All sounds good. POH launches its personal care products on the...

All sounds good. POH launches its personal care products on the world’s market (small but first step). However, an oxycodone patch might be this long awaited success story in a near future. Happy to hold POH.

Still believe the below article has its merit.

Phosphagenics buoyed by success of oxycodone patch trial for drug delivery.

Phosphagenics (ASX: POH) has successfully completed a Phase 1 clinical study of its patented oxycodone transdermal matrix patch system used for sustained release of pain management drugs.
The results of the trial established that after a single dose, the patch delivered oxycodone into the blood stream in a reproducible, consistent, and sustained manner.
The profile of the oxycodone patch appears potentially very suitable for chronic pain management, according to the study report. After a dose of oral oxycontin pain relief is provided for only a matter of hours.
The use of Phosphagenics’ oxycodone patch may provide sustained drug delivery for a matter of days, thus removing some of the peaks and troughs of pain relief associated with oral treatment
With sales exceeding $US1.5 billion annually, oxycodone, an opioid derivative, is one of the world’s leading drugs for pain management.
Chief operating officer of Phosphagenics Dr Esra Ogru said the oxycodone Phase 1 trial results are a world first and represent the potential of a significant breakthrough in the treatment of chronic pain.
He said the company is developing a treatment regime that will lead to therapeutic pain reduction and provide clinicians with more flexibility for treating patients, he said.
The company’s next trial, scheduled to be completed before the end of this year, will involve a repeat daily dosing study and will examine oxycodone blood levels over a longer period.
Although oxycodone is more potent than morphine, it produces less adverse side effects. Currently the drug can only be administered orally or intravenously.
Phosphagenics aims to become the first company to offer chronic pain sufferers, such as cancer patients, an oxycodone gel or patch that will provide sustained pain relief.

Investors interested in Phosphagenics Limited

§ Alliance Pharma plc (AIM: APH)
§ Amphion Innovations (LON: AMP)
§ Asterand (LSE: ATD)
§ Biocompatibles (LSE: BII)
§ Bionomics Limited (ASX: BNO)
§ Circadian Technologies Limited (ASX: CIR)
§ CogState Limited (ASX: CGS)
§ ImmuPharma Plc (AIM: IMM)
§ Lipoxen Plc (AIM: LPX)
§ QRxPharma Ltd (ASX: QRX)
§ Sinclair Pharma plc (AIM: SPH)
§ Starpharma (ASX: ASX:SPL)
§ Stirling Products Limited (ASX: STI)
http://www.proactiveinvestors.com.au/companies/news/2544/phosphagenics-buoyed-by-success-of-oxycodone-patch-trial-for-drug-delivery-2544.html

Cheers nj:)